Cargando…

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)

Isavuconazonium sulfate (Cresemba; Astellas Pharma Inc.), a water-soluble prodrug of the triazole antifungal agent isavuconazole, is available for the treatment of invasive aspergillosis (IA) and invasive mucormycosis. A population pharmacokinetic (PPK) model was constructed using nonparametric esti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovanda, Laura L., Desai, Amit V., Lu, Qiaoyang, Townsend, Robert W., Akhtar, Shahzad, Bonate, Peter, Hope, William W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958143/
https://www.ncbi.nlm.nih.gov/pubmed/27185799
http://dx.doi.org/10.1128/AAC.00514-16
_version_ 1782444276900167680
author Kovanda, Laura L.
Desai, Amit V.
Lu, Qiaoyang
Townsend, Robert W.
Akhtar, Shahzad
Bonate, Peter
Hope, William W.
author_facet Kovanda, Laura L.
Desai, Amit V.
Lu, Qiaoyang
Townsend, Robert W.
Akhtar, Shahzad
Bonate, Peter
Hope, William W.
author_sort Kovanda, Laura L.
collection PubMed
description Isavuconazonium sulfate (Cresemba; Astellas Pharma Inc.), a water-soluble prodrug of the triazole antifungal agent isavuconazole, is available for the treatment of invasive aspergillosis (IA) and invasive mucormycosis. A population pharmacokinetic (PPK) model was constructed using nonparametric estimation to compare the pharmacokinetic (PK) behaviors of isavuconazole in patients treated in the phase 3 VITAL open-label clinical trial, which evaluated the efficacy and safety of the drug for treatment of renally impaired IA patients and patients with invasive fungal disease (IFD) caused by emerging molds, yeasts, and dimorphic fungi. Covariates examined were body mass index (BMI), weight, race, impact of estimated glomerular filtration rate (eGFR) on clearance (CL), and impact of weight on volume. PK parameters were compared based on IFD type and other patient characteristics. Simulations were performed to describe the MICs covered by the clinical dosing regimen. Concentrations (n = 458) from 136 patients were used to construct a 2-compartment model (first-order absorption compartment and central compartment). Weight-related covariates affected clearance, but eGFR did not. PK parameters and intersubject variability of CL were similar across different IFD groups and populations. Target attainment analyses demonstrated that the clinical dosing regimen would be sufficient for total drug area under the concentration-time curve (AUC)/MIC targets ranging from 50.5 for Aspergillus spp. (up to the CLSI MIC of 0.5 mg/liter) to 270 and 5,053 for Candida albicans (up to MICs of 0.125 and 0.004 mg/liter, respectively) and 312 for non-albicans Candida spp. (up to a MIC of 0.125 mg/liter). The estimations for Candida spp. were exploratory considering that no patients with Candida infections were included in the current analyses. (The VITAL trial is registered at ClinicalTrials.gov under number NCT00634049.)
format Online
Article
Text
id pubmed-4958143
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-49581432016-07-26 Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study) Kovanda, Laura L. Desai, Amit V. Lu, Qiaoyang Townsend, Robert W. Akhtar, Shahzad Bonate, Peter Hope, William W. Antimicrob Agents Chemother Pharmacology Isavuconazonium sulfate (Cresemba; Astellas Pharma Inc.), a water-soluble prodrug of the triazole antifungal agent isavuconazole, is available for the treatment of invasive aspergillosis (IA) and invasive mucormycosis. A population pharmacokinetic (PPK) model was constructed using nonparametric estimation to compare the pharmacokinetic (PK) behaviors of isavuconazole in patients treated in the phase 3 VITAL open-label clinical trial, which evaluated the efficacy and safety of the drug for treatment of renally impaired IA patients and patients with invasive fungal disease (IFD) caused by emerging molds, yeasts, and dimorphic fungi. Covariates examined were body mass index (BMI), weight, race, impact of estimated glomerular filtration rate (eGFR) on clearance (CL), and impact of weight on volume. PK parameters were compared based on IFD type and other patient characteristics. Simulations were performed to describe the MICs covered by the clinical dosing regimen. Concentrations (n = 458) from 136 patients were used to construct a 2-compartment model (first-order absorption compartment and central compartment). Weight-related covariates affected clearance, but eGFR did not. PK parameters and intersubject variability of CL were similar across different IFD groups and populations. Target attainment analyses demonstrated that the clinical dosing regimen would be sufficient for total drug area under the concentration-time curve (AUC)/MIC targets ranging from 50.5 for Aspergillus spp. (up to the CLSI MIC of 0.5 mg/liter) to 270 and 5,053 for Candida albicans (up to MICs of 0.125 and 0.004 mg/liter, respectively) and 312 for non-albicans Candida spp. (up to a MIC of 0.125 mg/liter). The estimations for Candida spp. were exploratory considering that no patients with Candida infections were included in the current analyses. (The VITAL trial is registered at ClinicalTrials.gov under number NCT00634049.) American Society for Microbiology 2016-07-22 /pmc/articles/PMC4958143/ /pubmed/27185799 http://dx.doi.org/10.1128/AAC.00514-16 Text en Copyright © 2016 Kovanda et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Pharmacology
Kovanda, Laura L.
Desai, Amit V.
Lu, Qiaoyang
Townsend, Robert W.
Akhtar, Shahzad
Bonate, Peter
Hope, William W.
Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
title Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
title_full Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
title_fullStr Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
title_full_unstemmed Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
title_short Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
title_sort isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the vital study)
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958143/
https://www.ncbi.nlm.nih.gov/pubmed/27185799
http://dx.doi.org/10.1128/AAC.00514-16
work_keys_str_mv AT kovandalaural isavuconazolepopulationpharmacokineticanalysisusingnonparametricestimationinpatientswithinvasivefungaldiseaseresultsfromthevitalstudy
AT desaiamitv isavuconazolepopulationpharmacokineticanalysisusingnonparametricestimationinpatientswithinvasivefungaldiseaseresultsfromthevitalstudy
AT luqiaoyang isavuconazolepopulationpharmacokineticanalysisusingnonparametricestimationinpatientswithinvasivefungaldiseaseresultsfromthevitalstudy
AT townsendrobertw isavuconazolepopulationpharmacokineticanalysisusingnonparametricestimationinpatientswithinvasivefungaldiseaseresultsfromthevitalstudy
AT akhtarshahzad isavuconazolepopulationpharmacokineticanalysisusingnonparametricestimationinpatientswithinvasivefungaldiseaseresultsfromthevitalstudy
AT bonatepeter isavuconazolepopulationpharmacokineticanalysisusingnonparametricestimationinpatientswithinvasivefungaldiseaseresultsfromthevitalstudy
AT hopewilliamw isavuconazolepopulationpharmacokineticanalysisusingnonparametricestimationinpatientswithinvasivefungaldiseaseresultsfromthevitalstudy